Tuesday, Pfizer announced that it expects sales of its COVID-19 vaccine, which it jointly developed with BioNTech, to reach $15 billion in 2021, and to increase even more if it signs more contracts with more countries.

This news came at a time when Pfizer announced its fourth quarter and full-year earnings in the 2021 financial forecast.

Pfizer expected sales for the full year of 2021 to range between $44.4 and $46.4 billion, in addition to sales of the COVID-19 vaccine.

Also Read: Over 100 million COVID-19 vaccines administered worldwide